In this video, Alexander Khoruts, MD talks about his team's randomized, double-blind study, which showed that fecal microbiota transplant therapy is safe to use for patients with acute myeloid leukemia...
Researchers examined if venetoclax—a therapy commonly used in the treatment of acute myelogenous leukemia and chronic lymphocytic leukemia—was associated with an increased risk of opportunistic infections,...
The American Cancer Society annually projects the number of new leukemia diagnoses in the United States. Which type of leukemia is projected to have the most diagnoses in 2024? Take the quiz to find out! ...
The American Cancer Society annually projects the number of new leukemia diagnoses in the United States. Which type of leukemia is projected to have the most diagnoses in 2024? Take the quiz to find out! ...
Acute myeloid leukemia is one of the most common types of leukemia in adults, but what is the incidence of this type of leukemia among overall cases of cancer? Find out with this pop quiz.
Do you know the primary purpose of consolidation cytarabine administration in the treatment of adults with acute myeloid leukemia, according to the poster discussion presented at ASCO 2023 titled "Outcomes...
In this video, Alexander Khoruts, MD talks about his team's randomized, double-blind study, which showed that fecal microbiota transplant therapy is safe to use for patients with acute myeloid leukemia...
In this podcast, Pinkal Desai, MD, discusses the impact of previous chemotherapy and/or radiation exposure in patients who go on to develop acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS),...
In this video, Ian Bouligny, MD, discusses his team’s research that aimed to determine the impact of secondary-type mutations in patients who were newly diagnosed with acute myeloid leukemia and treated...
In this video, Kendall Diebold, DNP, FNP-C, speaks about her team’s research titled “Outcomes of 3- Versus 5-Day Administration Schedule of Consolidation Cytarabine in Adults with Acute Myeloid Leukemia,”...
In this interview, Ian Bouligny, MD, answers questions about his team’s research that sought to determine the use of venetoclax-based strategies in patients with newly diagnosed secondary-type mutations of...